Concepedia

Petr Krivorotko

PK

Statistics

Publications

11

Citations

1.1K

H-Index

11

Active since

2016

Affiliations

Institute of Oncology NN Petrov(Current)

Fudan University Shanghai Cancer Center

The Christie NHS Foundation Trust

Instituto Nacional de Enfermedades Neoplásicas

Samsung Medical Center

Petr Krivorotko is an author at Institute of Oncology NN Petrov specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2016–2024

11

Publications

11

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 704 citations · Full text

, , +16

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Miguel Martín, A. Chan, Luc Dirix et al. · Annals of Oncology · 2016 · 185 citations · Full text

, , +15

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto et al. · British Journal of Cancer · 2018 · 60 citations · Full text

, , +15

Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Mafalda Oliveira, Hope S. Rugo, Sacha J. Howell et al. · The Lancet Oncology · 2024 · 41 citations

, , +17

Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients

Anna P. Sokolenko, Tatiana N. Sokolova, Elena V. Preobrazhenskaya et al. · Breast Cancer Research and Treatment · 2020 · 38 citations

, , +10

1–5 of 11